Alaunos Therapeutics (NASDAQ: TCRT) details board, pay and ownership in 10-K/A
Alaunos Therapeutics (NASDAQ: TCRT) has filed an amended annual report (10-K/A) to provide detailed information on its board structure, executive and director compensation, and significant shareholder ownership, which was initially omitted from its original 10-K filing. The amendment reaffirms a four-member board led by CEO Holger Weis and outlines various agreements, equity incentive plans, and audit fees, without altering previously reported financial statements. Key figures include a market value of non-affiliate holdings at $9.6 million and Robert W. Postma as the largest beneficial owner with 18.28% of shares.
APR 15·Investing.com▼
Alaunos Therapeutics receives Nasdaq notice for non-compliance with equity rule
Alaunos Therapeutics (NASDAQ:TCRT) has received a notice from Nasdaq for non-compliance with its listing rule requiring a minimum of $2.5 million in stockholders’ equity, as the company reported $2.153 million. The company must submit a compliance plan within 45 days and is exploring options to regain compliance, though there's no guarantee of acceptance or successful resolution. Non-compliance could lead to delisting, but Alaunos would have the right to appeal before a Nasdaq hearings panel.
APR 1·TradingView→
Alaunos Therapeutics 10-K: Revenue $0.005M, Net loss $4.176M
Alaunos Therapeutics reported minimal revenue and a net loss for the year, primarily due to operating expenses. The company has pivoted its programs from oncology to an obesity/metabolic program, which has shown promising preclinical results. Future advancement of this program is contingent on securing additional capital and strategic partnerships.
